Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium.
In: Marketwired, 2024-01-04
Zeitungsartikel
Zugriff:
Titel: |
Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium.
|
---|---|
Zeitschrift: | Marketwired, 2024-01-04 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|